Select Page

Eur Radiol (2017) 27:2737–2743 DOI 10.1007/s00330-016-4612-z

Η Ευρωπαϊκή Εταιρία Απεικόνισης Μαστού (EUSOBI) καθώς και 30 εθνικοί οργανισμοί Ακτινολογίας Μαστού, υποστηρίζουν σθεναρά τη μαστογραφία ως εξέταση για τα προγράμματα προσυμπτωματικού πληθυσμιακού ελέγχου, η οποία έχει ως αποτέλεσμα μια σημαντική ελάττωση της θνησιμότητας από τον καρκίνο του μαστού και που οδηγεί στη μείωση της συμπληρωματικής τοπικής και συστημικής θεραπείας, σε γυναίκες που υποβάλλονται σε αυτά τα προγράμματα. Οργανισμοί αλλά και μεμονωμένα άτομα που αμφισβητούν την εγκυρότητά της παρά το μεγάλο όγκο αποδεικτικών στοιχείων που έχουν συγκεντρωθεί σε ένα χρονικό διάστημα πλέον των τριών δεκαετιών, θέτουν τη ζωή των γυναικών σε κίνδυνο.

Έγγραφο διατύπωσης θέσεων σχετικά με τον προσυμπτωματικό έλεγχο για τον καρκίνο του μαστού από την Ευρωπαϊκή Εταιρία Απεικόνισης Μαστού (EUSOBI) και 30 εθνικούς οργανισμούς ακτινολογίας μαστού. Αυστρία, Βέλγιο, Βοσνία και Ερζεγοβίνη, Βουλγαρία, Γαλλία, Γερμανία, Δανία, Ελλάδα, Εσθονία, Ελβετία, Ισλανδία, Ιρλανδία, Ιταλία, Ισπανία, Ισραήλ, Κροατία, Τσεχοσλοβακία, Λιθουανία, Μολδαβία, Νορβηγία, Ουγγαρία, Ολλανδία, Πολωνία, Πορτογαλία, Ρουμανία, Σερβία, Σλοβακία, Σουηδία, Τουρκία και Φινλανδία.

Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey

Abstract

EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40% for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evi- dence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second pri- ority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alter- natives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammogra- phy (not film-screen or phosphor-plate computer radiogra- phy) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or inter- national guidelines and recommendations are encouraged.

Introduction

This position paper on screening for breast cancer (BC) has been proposed by the Executive Board and the Scientific Committee of the European Society of Breast Imaging (EUSOBI) and approved by 30 national breast radiology bodies/sections (Table 1). The aim is to give a clear message in favour of screening mammography to national/local governments, policy makers, referring physicians and the general population.

 

Breast cancer as a major health issue and the role of mammography in early diagnosis

All over the world, BC remains a major issue for public health. Increasing numbers of new cases and deaths are observed in both developed and less developed countries, only partially attributable to the increasing population age. In the 28 member states of the European Union, there were 361,608 new BC cases in 2012 and these are estimated to have increased to 373,733 in 2015 (+3.4 %); deaths were 91,585 and 95,357, respectively (+4.1 %) [1]. No major differences in this trend can be appreciated across European countries. Notwithstanding its intrinsic limitations in terms of sensitiv- ity and specificity, mammography remains the main tool for population-based mass screening with demonstrated effective- ness in reducing mortality and allowing for conservative treat- ment, as already stated by EUSOBI [2]. Tumour stage at diag- nosis of BC still significantly impacts on overall survival even in the current era of effective systemic therapy. Thus, early diagnosis remains crucial. This principle has been recently con- firmed by an interesting population-based study from the Netherlands Cancer Registry, which evaluated more than 170,000 BC patients. The proportion of patients receiving neoadjuvant/adjuvant systemic therapy increased from 53 % in 1995–2005 to 60 % in 2006–2012. However, in 2006– 2012 the mortality for larger tumours remained greater than that for smaller tumours, significantly for the comparison of T1c and T1a stage, and was independent from nodal status [3].

The evidence in favour of screening mammography has been recently summarized by the International Agency for Research on Cancer (IARC) [4]. Upon randomized controlled trials, the reduction in BC mortality due to screening mam- mography is confirmed for women between 50 and 69 years of age. Considering 20 cohort studies and 20 case-control studies, the estimated reduction in BC mortality is 40 % for women aged 50–69 years who take up the invitation and 23 % when also including those who do not accept the invitation, as a societal effect of the screening policy. From cohort studies, a mortality reduction has also been estimated for women aged 40–49 years and 70–74 years, though the evidence from published studies was considered to be “limited”. Available data did not allow the IARC work- ing group to define an optimal screening interval. However, we should consider that the majority of European countries opted for biennial screening in the 50- to 69-year-old cohort. When 40- to 49-year-old cohort is invited, the yearly interval is generally adopted in consideration of a potential higher speed of BC growth and of a lower sensitivity of mammogra- phy due to the higher breast density. The average cumulative risk for a false-positive recall in organized screening programmes has been evaluated by the IARC working group to be about 20 % for women aged 50– 69 years who have ten screens in 20 years, while the needle biopsy rate for a false-positive finding is lower than 1 % per round [4]. In addition, it should be noted that screening mam- mography allows for both downscaling clinico-pathological features of invasive BCs and reducing the impact of loco- regional and adjuvant treatments [5–8]. With regard to overdiagnosis (i.e. the rate of screen- diagnosed BCs otherwise unnoticed during the patient’s life- time), the IARC working group accepted the estimate provid- ed by the Euroscreen working group [9], equal to 6.5 % (range 1–10 %), which was calculated on the basis of the difference in the cumulative probability of a BC diagnosis among wom- en receiving or not receiving screening mammography, takin into account lead time and underlying increasing incidence. If these factors are carefully considered, a similar estimate of overdiagnosis (4–11 %) is also obtained from randomized controlled trials [4]. Notably, while overdetection (resulting from a specific action by the breast radiologist evaluating a finding as suspicious) should be distinguished from overdiag- nosis (which also implies an essential role of the pathologist) [10], further efforts should be dedicated to the reduction of the most important negative consequences of overdiagnosis, i.e. overtreatment.

Risk of radiation-induced breast cancer

Radiation-induced BCs from mammography were estimated, based on models including different factors. For the 50- to 69- year age group, taking into account a latency time of 10 years and a dose of 2.5 mGy per screening round, the risk of radiation-induced BC death has been estimated to be 1 per 100,000 screened women. The risk of radiation-induced BC due to screening mammography is at least 100 times lower than the probability of avoiding a BC death [4]. Applying a mortality reduction rate of 43 %, biennial screening mammog- raphy performed in 100,000 women saves 350 lives [11]. For the 40- to 49-year age group, the problem of radiation effects must be more carefully considered and depends on the esti- mated magnitude of radiation- induced BCs. Importantly, most of radiation-induced BCs will be cured [12].

Screening models

On the basis of the available evidence, the EUSOBI and the above-listed national breast radiology bodies strongly support screening mammography of the female population at average BC risk, typically from 50 to 69 years of age; extension of thi up to 73–75 years, biennially, is a second priority. Extension from 40 or 45–49, with annual screening, can be evaluated as a third priority, country-by-country. Age selection and screen- ing interval should be adapted to national demographics and local priorities. Importantly, these societies strongly discour- age the use of methods for screening such as thermography or other optical imaging tools as an alternative to mammography [13]. Moreover, these societies also discourage the use of ul- trasound as a primary screening tool in asymptomatic European women at average risk of BC.

Preference should be given to population-based screen- ing programmes on a regional/national basis with double reading rather than spontaneous mammographic screening with a single reading, given the advantages of the former in terms of higher specificity and positive predictive value [14, 15], lower cost, as well as structured quality controls and central data management. This concept has also been recently reinforced by the IARC working group in the above-mentioned paper [4].

In a wider framework, the EUSOBI and the above-listed national breast radiology bodies are aware of the open debate in other contexts such as that in the USA where the Society of Breast Imaging and the American College of Radiology sup- port annual screening mammography from the age of 40 years by informing women on the advantages of early BC diagnosis [16]. The recent recommendations of the American Cancer Society [17] can be a reference for the US context: (1) regular screening mammography starting at age 45 years (strong rec- ommendation); (2) annual screening mammography from 45– 54 years of age (qualified recommendation); (3) from 55 years of age, transition to biennial or continuing annually (qualified recommendation); (4) opportunity to begin annual screening from 40–44 years (qualified recommendation); (6) continue screening mammography as long as women’s overall health is good and they have a life expectancy of ≥10 years (qualified recommendation); (7) no suggestion for screening clinical breast examination at any age (qualified recommendation).

Breast density

The EUSOBI and the above-listed national breast radiology bodies are aware of the masking effect of increased breast density, strongly impacting on the sensitivity of screening mammography, declining from 86–89 % for almost entirely fatty breasts to only 62–68 % for extremely dense breasts [18]. Studies aimed at reducing this negative effect by means of supplemental screening tools, such as manual or automated breast ultrasound, are welcome, especially when evaluating the cost-effectiveness of the additional tools on the large scale of population-based screening programmes. These societies also take into consideration the role of breast density as an independent BC risk factor, although this factor can be overated [19, 20], especially when reported as a communication to the women. In studies with a control group not limited to fatty breasts, the relative risk of women with dense breasts dropped to 2 or less [21, 22]. At any rate, these societies consider the general adoption of direct digital mammography to be the first priority to improve the sensitivity in women with increased breast density.

The potential of digital breast tomosynthesis

These societies also consider the increasing evidence in favour of digital breast tomosynthesis (DBT) as a screen- ing tool. Three prospective studies showed that DBT used as an adjunct [23–25] or alternative [26] to two- dimensional (2D) digital mammography allows for a su- perior diagnostic performance when compared to the lat- ter alone. Overall, DBT increases the detection rate from 0.5 to 2.7 per 1,000 screened women and reduces the recall rate from 0.8 to 3.6 per 100 screened women [27]. Of note, DBT is now proposed along with synthetic 2D views, practically solving the problem of an in- creased radiation exposure when DBT is performed as an adjunct to 2D digital mammography [28–30]. All these aspects will probably also confer to DBT the status of future “routine mammography” in the screening set- ting. However, before introducing DBT in BC screening outside trials approved by ethical committees, we need evidence for a statistically significant and clinically rele- vant reduction in the interval cancer rate. This cautious- ness is due to the need to avoid an increase in overdiag- nosis and costs, in the absence of the demonstration of cost-effectiveness of screening DBT (proof of which may require very long studies). First results on a reduction from 0.7 to 0.5 interval cancers per 100 screened women were very recently reported from a large study in the USA [31], but further evidence is needed. Moreover, the probable increase in reading time associated with the use of DBT in screening [32] and its effects on sus- tainability of screening programmes should be considered before routine implementation.

Preference for digital instead of f ilm-screen mammography

Overall, looking at the course of technological evolution of mammography in the last decades and at the current trend in favour of DBT, these societies strongly support the adoption of direct digital mammography (not phosphor-plate computer radiography) instead of film-screen mammography in all countries. In fact, digital mammography implies many sub- stantial advantages, including lower dose, higher image quality, possibility of post-processing, digital archiving, image transmission and no chemical pollution. We suggest that new mammographic units should be based on direct digital mam- mography technology and, when possible, equipped with DBT in readiness for the next evolution

Need for certified and subspecialty-trained radiologists in the context of breast centres

Screening mammograms, with or without DBT, should be read by radiologists qualified as screening mammography readers. Proficiency tests at the regional/national/European level are encouraged in order to guarantee a standardized reading quality together with minimum screening numbers read per year. It is essential that there is a continuity of care from screen- ing mammography to diagnostic breast imaging, to needle sampling and treatment planning either in the context of a dedicated breast centre or in a screening centre that has a well-organized relationship with a diagnostic imaging facility. Whenever possible, radiologists should operate in the context of integrated breast units with the help of organized/structured cooperation among BC specialists. Quality assurance programmes regarding breast radiology units/sections are also encouraged in the context of forthcom- ing new European guidelines for BC screening, diagnosis and treatment.

Preference for core or vacuum-assisted biopsy

Preference should be given to needle sampling of breast le- sions using core biopsy or vacuum-assisted biopsy instead of fine needle aspiration [33], in consideration of the lower false- negative rate and/or inadequate sampling, unless strict coop- eration with a cytologist allows for a demonstrable equally high diagnostic performance. This preference does not apply for sampling of lymph nodes suspected to be metastatic at ultrasound of axilla, where fine needle aspiration has been shown to be effective [34].

Women at increased risk for breast cancer

These societies are in favour of including, whenever possible, dedicated pathways for high-risk women (lifetime risk equal to or higher than 20 %), offering magnetic resonance imaging according to national or international guidelines and recom- mendations [35–37]. In this regard, policies will be different, considering the heterogeneity of health systems across coun- tries. Studies considering risk stratification for different screen- ing strategies of women at increased BC risk are welcome.

Summary statement

EUSOBI and 30 national breast radiology bodies strongly support mammography as a population-based mass screening tool which results in a relevant reduction in BC mortality and leads to a favourable decrease in both loco-regional and adju- vant treatments in women attending these programmes. People and institutions questioning its validity despite a large body of evidence accumulated in more than three decades put women’s lives at risk.

References

  1. Globocan Online Analysis (http://globocan.iarc.fr/Pages/burden_ sel.aspx, accessed on June 3, 2016)
  2. Sardanelli F, Helbich TH, European Society of Breast Imaging (EUSOBI) (2012) Mammography: EUSOBI recommendations for women’s information. Insights Imaging 3(1):7–10
  3. Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on sur- vival in modern times: population based study in 173,797 patients. BMJ 351:h4901
  4. Lauby-Secretan B, Scoccianti C, Loomis D, International Agency for Research on Cancer Handbook Working Group et al (2015) Breast Cancer Screening – Viewpoint of the IARC Working Group. N Engl J Med 372(24):2353–2358
  5. Hofvind S, Sørum R, Thoresen S (2008) Incidence and tumor char- acteristics of breast cancer diagnosed before and after implementa- tion of a population-based screening-program. Acta Oncol 47(2): 225–231
  6. Cutuli B, Dalenc F, Cottu PH et al (2015) Impact of screening on clinicopathological features and treatment for invasive breast can- cer: results of two national surveys. Cancer Radiother 19(5):295– 302
  7. Dong W, Berry DA, Bevers TB et al (2008) Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomark 17(5):1096–1103
  8. Nagtegaal ID, Allgood PC, Duffy SW et al (2011) Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 117(7):1360–1368
  9. Paci E, EUROSCREEN Working Group (2012) Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen 19(Suppl 1):5–13

Eur Radiol (2017) 27:2737–2743 2743

  1. Colin C, Devouassoux-Shisheboran M, Sardanelli F (2014) Is breast cancer overdiagnosis also nested in pathologic misclassifica- tion? Radiology 273(3):652–655
  2. Hauge IH, Pedersen K, Olerud HM, Hole EO, Hofvind S (2014) The risk of radiation-induced breast cancers due to biennial mam- mographic screening in women aged 50-69 years is minimal. Acta Radiol 55(10):1174–1179
  3. Yaffe MJ, Mainprize JG (2011) Risk of radiation-induced breast cancer from mammographic screening. Radiology 258(1):98–105
  4. Brkljacić B, Miletić D, Sardanelli F (2013) Thermography is not a feasible method for breast cancer screening. Coll Antropol 37(2): 589–593
  5. Kemp Jacobsen K, Abraham L, Buist DS et al (2015) Comparison of cumulative false-positive risk of screening mammography in the United States and Denmark. Cancer Epidemiol 39(4):656–663
  6. Kemp Jacobsen K, O’Meara ES, Key D et al (2015) Comparing sensitivity and specificity of screening mammography in the United States and Denmark. Int J Cancer 137(9):2198–2207
  7. Society of Breast Imaging. https://www.sbi-online.org/Portals/0/ Position%20Statements/2016/SBI%20ACR%20Response%20 to%20 USPSTF%20Recommendations.pdf. Accessed on February 8, 2016
  8. Oeffinger KC, Fontham ET, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314(15):1599–1614
  9. Freer PE (2015) Mammographic breast density: impact on breast cancer risk and implications for screening. RadioGraphics 35(2): 302–315
  10. Colin C, Prince V, Valette PJ (2013) Can mammographic assess- ments lead to consider density as a risk factor for breast cancer? Eur J Radiol 82(3):404–411
  11. Colin C, Schott AM, Valette PJ (2014) Mammographic density is not a worthwhile examination to distinguish high cancer risk wom- en in screening. Eur Radiol 24(10):2412–2416
  12. Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP et al (2016) Comparison of clinical and automated breast density measure- ments: Implications for risk prediction and supplemental screening. Radiology 279(3):710–719
  13. McCormack VA, dos Santos SI (2006) Breast density and paren- chymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15(6):1159–1169
  14. Skaane P, Bandos AI, Gullien R et al (2013) Comparison of digital mammography alone and digital mammography plus tomosynthesis in a population-based screening program. Radiology 267(1):47–56
  15. Skaane P, Bandos AI, Gullien R et al (2013) Prospective trial com- paring full-field digital mammography (FFDM) versus combined FFDM and tomosynthesis in a population-based screening pro- gramme using independent double reading with arbitration. Eur Radiol 23(8):2061–2071
  16. Ciatto S, Houssami N, Bernardi D et al (2013) Integration of 3D digital mammography with tomosynthesis for population breast-cancer screening (STORM): a prospective comparison study.

Lancet Oncol 14(7):583–589
26. Lång K, Andersson I, Rosso A, Tingberg A, Timberg P, Zackrisson S (2016) Performance of one-view breast tomosynthesis as a stand- alone breast cancer screening modality: results from the Malmö Breast Tomosynthesis Screening Trial, a population-based study. Eur Radiol 26(1):184–190

27. Houssami N (2015) Digital breast tomosynthesis (3D-mammography) screening: data and implications for population screening. Expert Rev Med Devices 12(4):377–379

28. Svahn TM, Houssami N, Sechopoulos I, Mattsson S (2015) Review of radiation dose estimates in digital breast tomosynthesis relative to those in two-view full field digital mammography. Breast 24(2):93– 99

29. Gur D, Zuley ML, Anello MI et al (2012) Dose reduction in digital breast tomosynthesis (TM) screening using synthetically recon- structed projection images: an observer performance study. Acad Radiol 19(2):166–171

30. Skaane P, Bandos AI, Eben EB et al (2014) Two-view Digital Breast Tomosynthesis screening with synthetically reconstructed projections images: comparison with digital breast tomosynthesis with full-field digital mammographic images. Radiology 271(3): 655–663

31. McDonald ES, Oustimov A, Weinstein SP, Synnestvedt MB, Schnall M, Conant EF (2016) Effectiveness of digital breast tomosynthesis compared with digital mammography: Outcomes analysis from 3 years of breast cancer screening. JAMA Oncol 2(6):737-743

32. Gilbert FJ, Tucker L, Young KC (2016) Digital breast tomosynthesis (DBT): a review of the evidence for use as a screen- ing tool. Clin Radiol 71(2):141–150

33. van Breest SV, Nederend J, Voogd AC et al (2013) Trends in breast biopsies for abnormalities detected at screening mammography: a population-based study in the Netherlands. Br J Cancer 109(1): 242–248

34. Castellano I, Deambrogio C, Muscarà F et al (2014) Efficiency of a preoperative axillary ultrasound and fine-needle aspiration cytology to detect patients with extensive axillary lymph node involvement. PLoS One 9(9), e106640

35. Saslow D, Boetes C, Burke W, American Cancer Society Breast Cancer Advisory Group et al (2007) American Cancer Society guidelines for breast screening with MRI as an adjunct to mammog- raphy. CA Cancer J Clin 57(2):75–89

36. Sardanelli F, Boetes C, Borisch B et al (2010) Magnetic resonance imaging of the breast: recommendations from the EUSOMA work- ing group. Eur J Cancer 46(8):1296–1316

37. Mann RM, Balleyguier C, Baltzer PA, European Society of Breast Imaging (EUSOBI), with language review by Europa Donna–The European Breast Cancer Coalition et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25(12):3669–3678

error: Content is protected !!